Gilead Pays $1.275 Billion for an Oral Macrocyclic Peptide: What the PepStar Deal Signals for the Next Wave of Peptide Drug Development

Key takeaways

• Gilead Sciences announced on 22 October 2026 that it will acquire PepStar Therapeutics' oral IL-23R inhibitor programme — led by Phase 1 asset HCXT-2001 — for $1.275 billion in upfront cash.
• HCXT-2001 is an oral macrocyclic peptide designed to inhibit the interleukin-23 receptor, a well-validated target across inflammatory bowel disease (IBD) and psoriasis.
• The macrocyclic ring architecture addresses two longstanding barriers to oral peptide dosing: susceptibility to digestive-enzyme degradation and poor intestinal absorption.
• The deal adds to an accelerating pattern of large-pharma investment in oral peptide formats, spanning immunology, metabolic disease, and oncology, during 2026.
• For UK research-procurement teams, the transaction reinforces demand for macrocyclic peptide reference standards, analytical reagents, and synthesis-platform capacity.

The transaction in detail

Gilead Sciences agreed to acquire PepStar Therapeutics' oral IL-23R inhibitor programme, including lead asset HCXT-2001, for $1.275 billion upfront. HCXT-2001 is an oral macrocyclic peptide with an extended half-life currently in Phase 1 testing. Gilead sees potential for the candidate alone or combined with emvistegrast as a daily oral IBD treatment, and the deal is expected to close in the fourth quarter of 2026.

The transaction will expand Gilead's inflammation and immunology pipeline, and under the agreement Gilead will obtain worldwide rights to HCXT-2001 and the broader oral IL-23R inhibitor programme developed by privately held PepStar Therapeutics.

The deal was announced three days after Gilead reported positive Phase 2 results for emvistegrast, its own once-daily oral treatment for ulcerative colitis. The sequencing suggests a deliberate strategy to assemble a portfolio of oral, non-injection options for IBD — a class where current standards of care rely overwhelmingly on chronic subcutaneous or intravenous biologics.

Gilead is set to pay $1.275 billion in upfront cash, subject to customary adjustments. The transaction is expected to close in Q4 2026 and is projected to reduce Gilead's GAAP and non-GAAP earnings per share by approximately $0.79 to $0.83 in that quarter. PepStar Therapeutics is a privately held, clinical-stage company based in Shanghai, China.

What HCXT-2001 is and why macrocyclic structure matters

HCXT-2001 is an investigational oral macrocyclic peptide designed to inhibit the interleukin-23 receptor, a target involved in immune-mediated inflammatory diseases. The drug candidate is currently in Phase 1 clinical trials and features an extended half-life that could support once-daily oral administration.

The macrocyclic format is central to understanding the asset's commercial logic. Peptides are typically administered by injection because the digestive environment of the gut breaks them down and because they are difficult for the intestines to absorb. HCXT-2001 is a macrocyclic peptide in which the amino acids that make up the peptide are formed into a ring. This shape keeps the peptide's amino acids from being exposed to digestive enzymes and also helps the drug pass through intestinal walls.

This structural characteristic distinguishes macrocyclic peptides from conventional linear peptides — the class most commonly encountered in research-use catalogues — and is why the format has attracted disproportionate capital in 2026. The closed ring constrains conformational flexibility, reduces susceptibility to proteolysis, and can improve membrane permeability, though these properties must be optimised compound by compound.

The IL-23 receptor is a validated therapeutic target. The IL-23 pathway is one of the most extensively validated targets in immunology, and injectable monoclonal antibodies that inhibit IL-23 signalling have become established therapies for moderate-to-severe plaque psoriasis and have also demonstrated clinical benefit in psoriatic arthritis and IBD. In 2026, the FDA approved the first oral IL-23 receptor-targeted therapy for adults with moderate-to-severe plaque psoriasis, validating the potential of oral IL-23-targeted therapies as a new treatment modality. HCXT-2001 targets the same receptor via a different molecular class — a macrocyclic peptide rather than a small molecule — and is being evaluated first in IBD, where the unmet need remains high.

Gilead's combination strategy

Gilead is evaluating the potential for HCXT-2001 as a standalone treatment or in combination with other investigational therapies, including emvistegrast, for patients with inflammatory bowel disease. Emvistegrast is Gilead's oral integrin inhibitor, positioning the company to build a daily oral combination regimen across complementary IBD pathways — a model that would sharply differentiate a future commercial offering from injectable biologics.

Gilead is positioning the asset as a potentially differentiated route to oral IL-23 pathway inhibition. Whether that differentiation — in terms of selectivity, tolerability profile, or dosing convenience — is ultimately borne out in later-stage trials remains to be seen; HCXT-2001 has not yet completed Phase 1.

Context: the oral macrocyclic peptide investment wave in 2026

The PepStar acquisition is not an isolated transaction. It sits within a broader pattern of large-pharma and late-stage venture interest in oral peptide chemistry that has accelerated throughout 2026.

Oral peptides moving into IBD — Gilead's $1.275 billion upfront bet on HCXT-2001 — illustrates big pharma's appetite for oral alternatives to injectable IL-23 biologics.

In the oncology space, TwoStep Therapeutics, a Stanford spinout, is building multi-specific peptide-drug conjugates rather than antibody-drug conjugates. Its lead asset TS-104 pairs a polyspecific integrin-binding peptide that engages five tumour-associated integrins with an MMAE payload, with Phase 1 first-in-human enrolment expected later in 2026.

Earlier in the year, peptide drug discovery company Syneron Bio closed a $150 million Series B round to support its macrocyclic peptide development platform. Founded in 2022, Syneron leverages artificial intelligence through its proprietary Synova peptide platform. Macrocyclic peptides have been described as a "goldilocks" drug class due to their ability to bridge the gap between small molecules and biologics, enabling the targeting of traditionally difficult disease pathways.

The investment rationale across these transactions converges on a common thesis: macrocyclic peptides can access targets that conventional small molecules cannot engage with sufficient selectivity, while avoiding the manufacturing cost and injection-site burden of biologics — provided oral bioavailability can be engineered.

Procurement and research implications

For UK laboratory procurement teams sourcing peptide research materials, the Gilead/PepStar deal has several practical implications worth tracking.

Demand for macrocyclic peptide reference standards. As programmes such as HCXT-2001 advance through clinical development, contract research organisations will require certified reference materials for assay development, pharmacokinetic modelling, and method validation. Early-stage demand for macrocyclic peptide standards is typically driven by academic and CRO collaborators rather than in-house pharmaceutical teams, and this feeds through to catalogue suppliers.

Analytical capability requirements. Macrocyclic peptides present distinct characterisation challenges compared to linear sequences. Their cyclic architecture complicates mass spectrometry fragmentation patterns and HPLC peak assignment. Laboratories supporting programmes in this compound class should ensure their analytical instrumentation — particularly high-resolution mass spectrometry — and their team competencies are appropriate for macrocyclic structures.

Supply chain geography. The PepStar deal brings Gilead an IL-23 receptor programme from PepStar Therapeutics, a privately held company based in Shanghai. Like several other recent oral-peptide acquisitions, including Novo Nordisk's September 2026 licensing of the once-weekly oral GLP-1/GIP agonist HRS-1596 from Jiangsu Hengrui for up to $2.6 billion, the Danish drugmaker paying $300 million upfront for a preclinical GLP-1/GIP dual receptor agonist, with potential milestones bringing the total to $2.6 billion, and a candidate designed for once-weekly oral dosing — the origin of the underlying chemistry is Chinese. Research procurement teams should factor in due-diligence requirements around country-of-origin documentation and supply-chain continuity when sourcing materials related to these programmes.

What remains unknown

HCXT-2001 is a Phase 1 asset. No published efficacy data in IBD patients exist as of the date of this article. The Phase 1 programme in healthy adults is designed to establish safety, tolerability, and pharmacokinetic parameters. Clinical proof of concept in the target population — ulcerative colitis or Crohn's disease — remains to be demonstrated, and the combination with emvistegrast is at an even earlier conceptual stage.

The $1.275 billion upfront payment reflects the strategic premium Gilead is willing to accept for early oral-peptide positioning in immunology, rather than a valuation anchored to de-risked clinical data. Research teams should distinguish between the commercial rationale for the transaction and the current state of the clinical evidence base.